NCT02927717Unknown不适用
An Italian Experience on Grade 3b Follicular Lymphoma
A.O.U. Città della Salute e della Scienza0 个研究点目标入组 60 人开始时间: 2016年10月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 主要终点
- Overall Response Rate
研究概览
简要总结
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.
Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of grade 3b Follicular Lymphoma
- •Age > 18 years
- •Front-line treatment with Rituximab containing chemotherapy
- •Availability of histological sample for central review
排除标准
- •Other lymphoma diagnosis
结局指标
主要结局
Overall Response Rate
时间窗: End of front-line treatment (evaluated from diagnosis up to 30 months)
Number of patients who achieve Complete Response or Partial Response after treatment
次要结局
- Progression Free Survival(From first response to last follow-up for at least 2 years (up to 15 years))
- Overall Survival(Date of last follow-up for at least 2 years (up to 15 years))
研究者
Barbara Botto
MD
A.O.U. Città della Salute e della Scienza
相似试验
已完成
3 期
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor BurdenLymphomaNCT00136552Lymphoma Study Association360
已完成
2 期
Safety and Efficacy of Fludarabine and Cyclophosphamide + RituximabFollicular LymphomaNCT00393107Gruppo Italiano Studio Linfomi54
终止
3 期
Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular LymphomaAnn Arbor Stage I Grade 1 Follicular LymphomaAnn Arbor Stage I Grade 2 Follicular LymphomaAnn Arbor Stage II Grade 1 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 1 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Non-Contiguous Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaNCT02320292Mayo Clinic20
招募中
3 期
Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 AntibodyEarly Stage Follicular Lymphoma WHO Grade 1/2 or 3aNCT05045664Heidelberg University100
终止
2 期
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone LymphomaFollicular Lymphoma, Grade 1Follicular Lymphoma Grade 2Follicular Lymphoma Grade IIIaMarginal Zone LymphomaMarginal Zone B Cell LymphomaLymphomaFollicular LymphomaNCT03919175Massachusetts General Hospital18